Premium
The State of the Art in the Development of Biosimilars
Author(s) -
McCamish Mark,
Woollett Gillian
Publication year - 2012
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1038/clpt.2011.343
Subject(s) - biosimilar , commercialization , medicine , clinical pharmacology , psychological intervention , business , intensive care medicine , pharmacology , marketing , nursing
The development of biologic therapeutics using advanced technology to copy and improve on nature's design of complex peptides, proteins, and glycoproteins has enabled the treatment of diseases in entirely new ways and brought unique and lifesaving treatments to many people. However, at least in part because of cost pressures, access to these truly amazing products has not been uniformly available; many patients do not qualify for these treatments, or the treatment is postponed until disabilities accumulate. The development of biosimilars—essentially copies of the original biologic drugs after patent expiration—allows for wider and, as important, earlier access to these agents because of their lower cost and consequently greater affordability. The development and commercialization of biosimilars can help address unmet medical needs by improving access to well‐established therapeutic interventions while improving health‐care affordability. Clinical Pharmacology & Therapeutics (2012); 91 3, 405–417. doi: 10.1038/clpt.2011.343